623 related articles for article (PubMed ID: 1838450)
1. Long-term immunologic tolerance induction in chimeric mice after bone marrow transplantation across major histocompatibility barriers: persistent or redeveloping immunologic responsiveness after prolonged survival.
Sugiura K; Yasumizu R; Iwai H; Inaba MM; Toki J; Ogura M; Hara I; Good RA; Ikehara S
Thymus; 1991 Nov; 18(3):137-53. PubMed ID: 1838450
[TBL] [Abstract][Full Text] [Related]
2. Studies of immunologic tolerance to host minor histocompatibility antigens following allogeneic bone marrow transplantation in mice.
Perreault C; Allard A; Brochu S; Poupart C; Fontaine P; Bélanger R; Gyger M
Bone Marrow Transplant; 1990 Aug; 6(2):127-35. PubMed ID: 2145050
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow transplantation with T-cell-depleted grafts. II. Reconstitution of immunohemopoietic functions in lethally irradiated mice transplanted with unseparated or T-cell-depleted bone marrow grafts disparate at minor histocompatibility antigens.
Leshem B; Tsuberi BZ; Lebendiker Z; Anafi-Ayalon M; Shalit M; Weiss L; Slavin S; Kedar E
Transplantation; 1987 Jun; 43(6):814-7. PubMed ID: 2954282
[TBL] [Abstract][Full Text] [Related]
4. Long-term (>1 year) analyses of chimerism and tolerance in mixed allogeneic chimeric mice using normal mouse combinations.
Hayashi H; Toki J; Zhexiong L; Sugiura K; Inoue K; Ikehara S
Stem Cells; 2000; 18(4):273-80. PubMed ID: 10924093
[TBL] [Abstract][Full Text] [Related]
5. Analysis of tolerance induction using triple chimeric mice: major histocompatibility complex-disparate thymus, hemopoietic cells, and microenvironment.
Cui W; Hosaka N; Miyake T; Wang X; Guo K; Cui Y; Li Q; Song C; Feng W; Li Q; Takaki T; Nishida T; Inaba M; Ikehara S
Transplantation; 2008 Apr; 85(8):1151-8. PubMed ID: 18431236
[TBL] [Abstract][Full Text] [Related]
6. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH
J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
[TBL] [Abstract][Full Text] [Related]
7. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
8. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
9. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
10. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
[TBL] [Abstract][Full Text] [Related]
11. Reconstitution of lymphoid tissues under the influence of a subclinical level of graft versus host reaction induced by bone marrow T cells or splenic T cell subsets.
Hirano M; Arase H; Arase-Fukushi N; Ogasawara K; Iwabuchi K; Miyazaki T; Good RA; Onoé K
Cell Immunol; 1993 Oct; 151(1):118-32. PubMed ID: 8402923
[TBL] [Abstract][Full Text] [Related]
12. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
[TBL] [Abstract][Full Text] [Related]
13. Development of tolerance to donor type and host type H-2 antigens following transplantation of allogeneic bone marrow in mice.
Levite M; Reisner Y
Bone Marrow Transplant; 1990 Jul; 6(1):37-44. PubMed ID: 2143954
[TBL] [Abstract][Full Text] [Related]
14. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
15. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
16. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a novel method to induce tolerance in adult mice across fully allogeneic (entire H-2 plus multiminor histocompatibility) antigen barriers, using supralethal irradiation followed by injection of syngeneic bone marrow cells plus (donor X recipient) F1 spleen cells.
Tomita Y; Himeno K; Mayumi H; Tokuda N; Nomoto K
Immunobiology; 1989 Jun; 179(2-3):214-29. PubMed ID: 2793203
[TBL] [Abstract][Full Text] [Related]
18. Treatment of systemic and organ-specific autoimmune disease in mice by allogeneic bone marrow transplantation.
Ikehara S; Nakamura T; Sekita K; Muso E; Yasumizu R; Ohtsuki H; Hamashima Y; Good RA
Prog Clin Biol Res; 1987; 229():131-46. PubMed ID: 3299389
[TBL] [Abstract][Full Text] [Related]
19. Leucyl-leucine methyl ester treatment of donor cells permits establishment of immunocompetent parent----F1 chimeras that are selectively tolerant of host alloantigens.
Thiele DL; Calomeni JA; Lipsky PE
J Immunol; 1987 Oct; 139(7):2137-42. PubMed ID: 3309052
[TBL] [Abstract][Full Text] [Related]
20. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
Johnson BD; Drobyski WR; Truitt RL
Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
